


**LISTING OF CLAIMS**

This listing of claims will replace all prior versions of claims in the application.

1. (Previously presented) A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent optionally substituted, fused benzene;

R<sub>C</sub> is -CH<sub>2</sub>-R<sub>L</sub>;

R<sub>L</sub> is optionally substituted phenyl; and

R<sub>N</sub> is hydrogen.


2-3. (Cancelled)

4. (Previously presented) A method according to claim 1, wherein the fused benzene is unsubstituted.

5. to 9. (Cancelled).

10. (Currently amended) A method according to claim 1, wherein R<sub>L</sub> is substituted by one or more substituents selected from the group consisting of: C<sub>1-7</sub> alkyl; C<sub>5-20</sub> aryl; C<sub>3-20</sub> heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; sulfonamido; acylamido acylamino; ureido; acyloxy; thiol; thioether; sulfoxide; and sulfone.

11. (Currently amended) A method according to claim 10, wherein  $R_L$  is substituted by an ~~acylamido, wherein the acylamido is a ureido group, or an amino, wherein the amino is a~~ sulfonamido group.
12. (Original) A method according to claim 1, wherein the disease mediated by PARP is cancer, and there is additionally administered to the subject chemotherapy or radiation therapy.
13. (Previously presented) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:


A and B together represent optionally substituted, fused benzene;

$R_C$  is  $-\text{CH}_2-R_L$ ;

$R_L$  is optionally substituted phenyl; and

$R_N$  is hydrogen.

14. (Currently amended) A compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent optionally monosubstituted, fused benzene;

R<sub>C</sub> is -CH<sub>2</sub>-R<sub>L</sub>;

R<sub>L</sub> is substituted phenyl, wherein the substituents are selected from the group consisting of: C<sub>6</sub>-

~~aryl~~; C<sub>3-20</sub> heterocyclyl; ester; amido; acyloxy; sulfonamido; ~~cyano~~; ureido; acylamide;

~~thioether, thiol, SO<sub>2</sub>R wherein R is C<sub>1-7</sub> alkyl, C<sub>3-20</sub> heterocyclyl or C<sub>5-20</sub> aryl, and sulfoxide, and~~  
optionally further substituted; and

R<sub>N</sub> is hydrogen.


15-16. (Cancelled)

17. (Previously presented) A compound according to claim 14, wherein the fused benzene is unsubstituted.

18. (Cancelled)

19. (Currently amended) A compound according to claim 14, wherein R<sub>L</sub> is substituted by ~~an acylamide, wherein the acylamide is a~~ ureido group, or a sulfonamido group.

20. (Previously presented) A pharmaceutical composition comprising a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof, wherein:

A and B together represent an optionally substituted, fused benzene;

R<sub>C</sub> is -CH<sub>2</sub>-R<sub>L</sub>;

R<sub>L</sub> is optionally substituted phenyl; and

R<sub>N</sub> is hydrogen;

and a pharmaceutically acceptable carrier or diluent.



21-22. (Cancelled)

23. (Previously presented) The pharmaceutical composition of claim 20, wherein the fused benzene is unsubstituted.

24. (Currently amended) The pharmaceutical composition of claim 20, wherein R<sub>L</sub> is substituted by one or more substituents selected from the group consisting of: C<sub>1-7</sub> alkyl; C<sub>6-20</sub> aryl; C<sub>3-20</sub> heterocyclyl; halo; hydroxy; ether; nitro; cyano; carbonyl groups; amino; sulfonamido; acylamido acylamino; ureido; acyloxy; thiol; thioether; sulfoxide; and sulfone.



25. (Currently amended) The pharmaceutical composition of claim 24, wherein R<sub>L</sub> is substituted by ~~an acylamido, wherein the acylamido is a ureido group, or an amino, wherein the amino is a sulfonamido group.~~

26. (Currently amended) A method of treatment of a disease of a human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of the formula:




or an isomer, salt, solvate, chemically protected form and prodrug thereof, and a pharmaceutically acceptable carrier or diluent.


27. (Currently amended) A method of potentiating tumour cells for treatment with ionising radiation or chemotherapeutic agents comprising administering to said cells a compound of formula:



or an isomer, salt, solvate, chemically protected form, and prodrug thereof.

28. (Currently amended) A compound of the formula:





or an isomer, salt, solvate, chemically protected form and prodrug thereof.